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Tubulointerstitial damage and progression of renal failure. The
present work reviews the mechanisms and close association be-
tween glomerular and tubular damage and its relationship to re-
nal functional impairment. In addition, we present an overview
of the pathways involved in the progression of tubulointerstitial
fibrosis and a brief summary of the treatments used to retard
the progression to end-stage renal failure.
This article will review briefly three aspects of the role
of tubulointerstitial damage in the progression of re-
nal failure: (1) the relationship between tubulointerstitial
damage and deterioration of renal function; (2) the pro-
gression of tubulointerstitial fibrosis; and (3) therapeutic
approaches to retard progression of renal disease.
TUBULOINTERSTITIAL DAMAGE AND RENAL
FUNCTION
The first report showing a correlation between tubu-
lointerstitial damage and impairment of renal function
was made more than three decades ago in studies of pa-
tients with persistent glomerulonephritis [1]. These obser-
vations have been amply confirmed in subsequent years
[2–4]. In specific diseases, such as diabetes, the increment
in interstitial fibrosis over time is directly correlated
with the decrease in creatinine clearance [5]. In con-
trast, the degree of glomerular injury does not correlate
as well with renal outcomes [1–5]. This is likely because
periglomerular fibrosis may lead to peritubular scarring
with hindrance of flow into the proximal tubule. In this
situation, the glomerulus may appear structurally normal
but, in essence, is “atubular.” The demonstration that the
number of atubular glomeruli far exceeds the number of
glomeruli with global sclerosis in the renal ablation model
[6] made evident that relatively preserved glomerular
structure does not imply a functioning nephron, and pro-
vides a ready explanation for the superiority of using
†Deceased July 30, 2005
Key words: tubulointerstitial fibrosis, tubulointerstitial damage, renal
function.
C© 2005 by the International Society of Nephrology
tubulointerstitial scores rather than glomerular scores in
the prediction of renal outcome. Tubulointerstitial dam-
age and reduction in glomerular filtration rate (GFR)
are inextricably associated. Tubuloglomerular feedback
would reduce GFR, if increased distal delivery results
in proximal tubular injury with reduced sodium reab-
sorption. Glomerular damage, resulting in postglomeru-
lar ischemia, is associated with downstream hypoxia and
unchecked oxidative stress, tubular injury, and even-
tual nephron loss that, in turn, impose hemodynamic
stress in the remaining nephron units. Tubulointersti-
tial injury may be due to direct tubular damage (result-
ing from toxic, obstructive, or ischemic mechanisms) or
may be a consequence of glomerular damage with the
passage of cytokines and growth factors into the urine.
Extensive studies by Kriz et al [7, 8] have elucidated
additional histopathologic pathways of tubulointerstitial
injury induced by glomerular damage. Degenerative and
inflammatory lesions cause cell bridges and fibrous ad-
hesions between the glomerular tuft and Bowman’s cap-
sule, which cause a diversion of part of the glomerular
filtrate toward the periglomerular areas. This misdirected
urine, as well as the protein leakage in the tubular urine,
causes interstitial inflammation and direct encroachment
of the tubule, disconnection from the glomerulus, and
functional nephron loss.
THE PROGRESSION OF TUBULOINTERSTITIAL
DAMAGE
Several factors play an important role in the progres-
sion of renal damage. Proteinuria may be a risk factor or
a marker of disease severity, but has been proven to be a
useful prognostic and therapeutic guide in the long-term
management of chronic renal damage [9]. Inappropri-
ate activation of the alternative pathway of complement
at the apical membrane of tubular cells may also play
a pathogenic role, likely mediated by the C5b-9 mem-
brane attack complex [10, 11]. Oxidative stress is both
a cause and consequence of interstitial inflammation.
Tissue hypoxia resulting from angiotensin-induced vaso-
constriction or structural disruption of peritubular
capillaries is a final common pathway in the develop-
ment of tubulointerstitial fibrosis. Hypoxia can activate
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Fig. 1. Injury to the renal tubulointersti-
tium induced by direct damage, protein-
uria, glomerular filtrate misdirected to the
periglomerular spaces, and oxidative stress
in conditions of reduction in postglomeru-
lar blood flow, which act on tubular ep-
ithelial cells, (1) induce a complex response
that involves multiple cytokine production
(2). Infiltration of immune cells follows the
chemoattractant cytokines upregulated by
IjBa. In turn, the activation of infiltrating
cells, particularly macrophages, results in a
further increment of the tubulointerstitial cy-
tokine pool (3). Resident fibroblasts prolif-
erate in response to platelet-derived growth
factor, epithelial growth factor, and TGF-b
(4), and tubular epithelial cells suffer a mes-
enchymal phenotype transition (epithelial-
mesenchymal transition or EMT) (5). These
are induced primarily by TGF-b with the par-
ticipation of the Smad and Rho protein sys-
tems, which results in their transformation in
myofibroblasts.
fibroblasts [12], trigger epithelial mesenchymal transdif-
ferentiation (EMT) [13], and induce tubular cell apop-
tosis [14]. Because chronic tubulointerstitial damage is
characterized by an increase in extracellular matrix, the
factors involved in the synthesis and degradation of met-
alloproteinases are of critical importance. These factors
have been authoritatively reviewed [15]. There is wide
recognition that infiltrating cells play a key role in the
chronic renal damage of any etiology [16]. The princi-
pal cells involved in collagen deposition are fibroblasts,
which may be resident, bone marrow–derived cells, and
tubular epithelial cells transformed in myofibroblasts by
a complex process of transdifferentiation in which renal
tubular cells lose their epithelial phenotype and acquire
mesenchymal characteristics (EMT) [17, 18]. Figure 1
shows an overview of the major steps involved in the de-
velopment of tubulointerstitial fibrosis. After Strutz et al
[19] postulated that EMT could represent a mechanism
for generating fibroblasts in the kidney, several investi-
gators found de novo expression of alpha smooth muscle
cell actin (aSMA) and actin filaments in tubular epithelial
cells three weeks after renal ablation [20]. Afterwards,
evidence of EMT was obtained in a variety of experi-
mental models of chronic renal damage [18]. The impor-
tance of this process was underlined by Yang et al [21],
who showed that in the absence of this process, myofi-
broblast accumulation was reversed. As described by Liu
[18], there are four key events in EMT: loss of adhesion
properties, de novo expression of aSMA and actin re-
organization, disruption of tubular basement membrane,
and enhanced cell migration of cells in transition from
epithelial to mesenchymal phenotype toward interstitial
areas. The process of EMT is regulated by a variety of fac-
tors that promote (transforming growth factor-b [TGF-
b], epithelial growth factor, interleukin 1, angiotensin II,
connective tissue growth factor [CTGF], advanced gly-
cation end products, matrix metalloproteinase-2, type I
collagen) or inhibit (bone morphogenic protein-7, hep-
atocyte growth factor) cellular transdifferentiation. The
intracellular pathways for EMT involve phosphorylation
of Smad-2 and Smad-3 that forms a complex with Smad-
4 and is translocated into the nucleus where it induces
the transcription of TGF-b responsive genes. In addition,
TGF-b activates other pathways, such as p38 MAPK and
RhoA. Interestingly, the EMT process may be potentially
reversible if chronic injury is suppressed [18]. Finally, in
addition to EMT, it is also likely that intrinsic fibroblasts
themselves can alter their phenotype into myofibroblasts
and thereby also contribute to the fibrotic process.
THERAPEUTIC APPROACHES TO RETARD
PROGRESSION OF END-STAGE RENAL
DAMAGE
Several treatments have been shown to halt or retard
the progression of chronic renal disease in experimental
animals and in humans. Some of these treatments have a
variety of effects that combine to have a beneficial effect,
whereas others are directed to modify specific steps in the
pathway leading toward renal fibrosis (Table 1). Among
the former, the suppression of the renin angiotensin sys-
tem is currently the most widely used in clinical practice.
It is now evident that the beneficial effects of angiotensin-
converting enzyme (ACE) inhibitors and angiotensin re-
ceptor type 1 blocker (ARB) are not only the result of
reducing glomerular hypertension, but are also due to
suppression of the proinflammatory and vasoconstrictor
actions of angiotensin II. A recent example of these mul-
tiple effects is given by the studies in the genetically hy-
perlipemic Imai rat strain [22] and the suppression of
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Table 1. Treatments used to retard progression of chronic renal
failure
Interventions that affect multiple systems involved in development of
fibrosis
Anti-angiotensin treatments (ACE inhibitors, ARB, combined
ACE+ARB, suppression of intrarenal angiotensinogen)
Statins
Nitric oxide donors
Mycophenolate mofetil
COX II inhibitors
Rapamycin
Pirfenidone
Relaxin
MCP-1 inhibitors
IjBa
Endothelin receptor blockade
Aldosterone antagonists
Retinoids
Erythropoietin
Vitamin D
VEGF
Interventions in specific pathways leading to tubulointerstitial fibrosis
HGF
BMP-7
ROCK inhibitors (Y-27632)
Anti-TGF-b neutralizing antibodies
Antisense CTGF
Imatinib mesylate
Abbreviations are: ACE, angiotensin-converting enzyme; ARB, angiotensin
receptor type 1 blocker; COX, cytochrome c oxidase; MCP-1, monocyte chemo-
tactic protein-1; VEGF, vascular endothelium growth factor; HGF, hepatocyte
growth factor; BMP-7, bone morphogenic protein-7; TGF-b , transforming
growth factor- b ; CTGF, connective tissue growth factor.
angiotensinogen gene expression in unilateral ureteral
obstruction [23]. Large, multicenter, randomized studies
have shown the value of ACE inhibitors and ARBs in re-
ducing proteinuria and delaying end-stage renal disease.
Relatively novel therapeutic strategies presently under
evaluation include the combined use of ACE and ARB
[24] and the use of very large doses of ACE inhibitors
[25]. Statins also belong to the group of therapies that
have several beneficial effects, in addition to their lipid-
lowering activity. Among them, the most recently demon-
strated benefit is the blockade of TGF-b-dependent
transcriptional activation of CTGF [26]. A number of
studies have shown that the treatments directed to in-
crease nitric oxide bioavailability are renoprotective [27–
29]. However, nitric oxide donors may exert cytotoxicity
by facilitating the formation of peroxynitrite from the
interaction of nitric oxide with superoxide [30], which
can limit their potential benefit in the treatment of re-
nal disease [31]. Immunosuppressive agents such as my-
cophenolate mofetil (MMF) have been used to reduce the
renal inflammatory infiltrate. We and others have shown
that MMF ameliorates the progression of renal damage
in the remnant kidney [32–34] and in the obese Zucker
rat [35], a model that resembles type II diabetes in hu-
mans in which we previously showed that angiotensin
type-1 receptors and inflammatory mediators are upregu-
lated [36]. The cellophane-wrapped (Page kidney) model,
which is characterized by significant tubulointerstitial in-
flammation, is another model in which chronic tubuloin-
terstitial inflammation and associated hypertension are
significantly ameliorated by MMF treatment [37]. The
beneficial effects of this drug are probably a combina-
tion of multiple mechanisms, because it not only inhibits
proliferation of immune cells, but also blocks prolifera-
tion of smooth muscle cells, mesangial cells, and fibrob-
lasts [38, 39]. Rapamycin is another immunosuppressive
drug that has proven to be of benefit in retarding the
progression of kidney damage. Recent studies indicate
that rapamycin reduced proliferation of tubular cells and
inhibits cystogenesis in the Han:SPRD rat model of poly-
cystic kidney disease [40]. Pirfenidone has been found to
reduce fibrosis in the renal ablation model, experimen-
tal ureteral obstruction, and cyclosporine nephropathy.
The mechanism of inhibition of fibrosis by pirfenidone is
incompletely elucidated; reduction in profibrotic gene ex-
pression, suppression of TGF-b or its effects, inhibition of
tumor necrosis factor-a, and downregulation of platelet-
derived growth factor expression have all been impli-
cated [41]. Relaxin reduces collagen deposition likely
because of stimulating ubiquitin-mediated degradation
[42, 43]. Antagonists of monocyte chemotactic protein-1
and reduction of IjBa activity by gene transfer of the
IjBa inhibitor have been shown to reduce macrophage
infiltration and interstitial fibrosis in protein overload
nephropathy [44, 45]. Several recent studies suggest that
selective and unselective endothelin-1 receptor antago-
nists [46], aldosterone antagonists [47], and retinoids [48]
also appear to be promising. Similarly, further investiga-
tions are required to expand a provocative recent inves-
tigation that has shown that 1,25-dihydroxy vitamin D
protects podocyte integrity and prevents glomeruloscle-
rosis and tubulointerstitial damage in the remnant kidney
model [49]. Improvement of tubulointerstitial hypoxia
by the preservation of capillary endothelium and rever-
sal of impaired angiogenesis is thought to play a role in
the beneficial effects found within the administration of
vascular endothelium growth factor in the remnant kid-
ney model [50]. Erythropoietin may also improve renal
disease in part via its ability to stimulate vascular en-
dothelium growth factor and angiogenesis [51]. There are
also interventions in specific pathways leading to tubu-
lointerstitial fibrosis (Table 1). Hepatocyte growth factor
prevents transcriptional activation of Smad promoters
(inducing snoN repressors) and reduces CTGF response
to TGF-b , resulting in inhibition of TGF-b signals and ac-
tivating matrix degradation. Systemic injection of hepato-
cyte growth factor reduces fibrosis in the remnant kidney
in rats [52] and in the mouse model of obstructive uropa-
thy [53]. Bone morphologic protein-7 reduces the nu-
clear translocation of the Smad 2/3/4 complex induced by
TGF-b and has been found to reduce fibrosis in obstruc-
tive and diabetic nephropathies primarily by inhibiting
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TGF-b-mediated EMT [54, 55]. Rho-associated coiled-
coil forming protein kinase (ROCK) inhibition has
recently been found also to suppress key steps in the
EMT, such as aSMA expression, cell migration, and inter-
stitial fibrosis in obstructive uropathy [56]. The systemic
administration of neutralizing antibodies that block TGF-
a activity prevented renal fibrosis and renal insufficiency
in the diabetic mice [57]. The administration of antisense
oligonucleotide to reduce the expression of CTGF in the
rat model of obstructive uropathy resulted in reduction
of collagen deposition and myofibroblast accumulation
[58]. Imatinib mesylate is an inhibitor of the abelson non-
receptor (c-abl) tyrosine kinase with the capacity to re-
duce fibroblast proliferation, which is currently used in
the treatment of chronic myelogenous leukemia. Recent
studies have shown that it is capable of reducing myofi-
broblast accumulation and collagen deposition in models
of obstructive uropathy, thus showing that not only TGF-
b-dependent pathways are important in the development
of renal fibrosis [59]. In summary, there are currently ef-
fective treatments to retard the progression of chronic
renal disease. Promising new therapies, targeted to sup-
press specific aspects of the pathways that lead to end-
stage renal disease, are in the process of being evaluated
for their capacity to prevent arrest and, hopefully, reverse
tubulointerstitial fibrosis.
ACKNOWLEDGMENTS
Work in Dr. Rodriguez-Iturbe’s lab is supported by grants from
FONACYT, Venezuela, and Asociacio´n de Amigos del Rin˜o´n,
Maracaibo.
Reprint requests to Bernardo Rodrı´guez-Iturbe, Apartado Postal
1430, Maracaibo 4001-A, Estado Zulia, Venezuela.
E-mail: bernardori@telcel.net.ve
REFERENCES
1. RISDON RA, SLOPER JC, DE WARDENER HE: Relationship between
renal function and histological changes found in renal biopsy spec-
imens from patients with persistent glomerular nephritis. Lancet
2:363–366, 1968
2. SCHAINUCK LI, STRICKER GE, CUTLER RE, BENDITT EP: Structural-
functional correlations in renal disease. II. The correlations. Human
Pathol 1:631–641, 1970
3. MACKENSEN-HAEN S, BADER R, GRUND KE, BOHLE A: Correlations
between renal cortical interstitial fibrosis, atrophy of the proxi-
mal tubules and impairment of the glomerular filtration rate. Clin
Nephrol 15:167–171, 1981
4. NATH KA: Tubulointerstitial changes as a major determinant in the
progression of renal damage. Am J Kidney Dis 20:1–17, 1992
5. GILBERT RE, COOPER ME: The tubulointerstitium in progressive di-
abetic kidney disease: More than an aftermath of glomerular injury?
Kidney Int 56:1627–1637, 1999
6. GANDHI M, OLSON JL, MEYER TW: Contribution of tubular in-
jury to loss of remnant kidney function. Kidney Int 54:1157–1165,
1998
7. KRIZ W, HOSSER H, HA¨HNEL B, et al: From segmental glomeru-
losclerosis to total nephron degeneration and interstitial fibrosis: A
histopathological study in rat models and human glomerulopathies.
Nephrol Dial Transpl 13:2781–2798, 1998
8. KRIZ W, LEHIR M: Pathways to nephron loss starting from glomeru-
lar diseases—Insights from animal models. Kidney Int 67:404–419,
2005
9. ZANDI-NEJAD K, EDDY AA, GLASSOCK RJ, BRENNER BM: Why is
proteinuria an ominous biomarker of progressive kidney disease?
Kidney Int Suppl 92:S76–S89, 2004
10. MORITA Y, NOMURA A, YUZAWA Y, et al: The role of complement in
the pathogenesis of tubulointerstitial lesions in rat mesangial pro-
liferative glomerulonephritis. J Am Soc Nephrol 8:1363–1372, 1997
11. NANGAKU M, PIPPIN J, COUSER WG: Complement membrane at-
tack complex (C5b-9) mediates interstitial disease in experimental
nephritic syndrome. J Am Soc Nephrol 10:2323–2331, 1999
12. NORMAN JT, CLARK IM, GARCIA PL: Hypoxia promotes fibrogenesis
in human renal fibroblasts. Kidney Int 58:2351–2366, 2000
13. MANOTHAM K, TANAKA T, MATSUMOTO M, et al: Transdifferentiation
of cultured tubular cells induced by hypoxia. Kidney Int 65:871–880,
2004
14. KAHN S, CLEVELAND RP, KOCH CJ, SCHELLING JR: Hypoxia induces
renal tubular cell apoptosis in chronic renal disease. Lab Invest
79:1089–1099, 1999
15. EDDY AA: Molecular insights into renal interstitial fibrosis. J Am
Soc Nephrol 7:2495–2508, 1996
16. RODRı´GUEZ-ITURBE B, PONS H, HERRERA-ACOSTA J, JOHNSON RJ:
The role of immunocompetent cells in non-immune renal diseases.
Kidney Int 59:1626–1640, 2001
17. IWANO M, NEILSON EG: Mechanisms of tubulointerstitial fibrosis.
Curr Opin Nephrol Hypertens 13:279–284, 2004
18. LIU Y: Epithelial to mesenchymal transition in renal fibrogenesis:
Pathologic significance, molecular mechanisms and therapeutic in-
tervention. J Amer Soc Nephrol 25:1–12, 2004
19. STRUTZ F, OKADA H, LO CW, et al: Identification and charac-
terization of a fibroblast marker: FSP1. J Cell Biol 130:393–405,
1995
20. NG YY, HUANG TP, YANG WC, et al: Tubular epithelial-myofi-
broblast transdifferentiation in progressive tubulointerstitial fibro-
sis in 5/6 nephrectomized rats. Kidney Int 54:864–876, 1998
21. YANG J, SHUKTZ RW, MARS WM, et al: Disruption of tissue-type
plasminogen activator gene in mice reduces renal interstitial fi-
brosis in obstructive nephropathy. J Clin Invest 110:1525–1538,
2002
22. RODRIGUEZ-ITURBE B, SATO T, QUIROZ Y, VAZIRI ND: AT-1 receptor
blockade prevents proteinuria, renal failure, hyperlipidemia and
glomerulosclerosis in the Imai rat. Kidney Int 66:668–675, 2004
23. SHIN G-T, KIM WH, YIM H, et al: Effects of suppressing intrarenal
angiotensinogen on renal transforming growth factor B1 expression
in acute ureteral obstruction. Kidney Int 67:897–980, 2005
24. WOLF G, RITZ E: Combination therapy with ACE inhibitors and
angiotensin II receptor blockers to halt progression of chronic renal
disease: Pathophysiology and indications. Kidney Int 67:799–812,
2005
25. ADAMCZAK M, GROSS ML, KRTIL J, et al: Reversal of glomeru-
losclerosis after high dose enalapril treatment in subtotally nephrec-
tomized rats. J Am Soc Nephrol 14:2833–2842, 2003
26. WATTS K, SPITERI M: Connective tissue growth factor expression
and induction by transforming growth factor-b is abrogated by sim-
vastatin via a Rho signaling mechanism. Am J Physiol Lung Cell
Mol Physiol 287:L1323–L3332, 2004
27. ZOJA C, BENIGNI A, CAMOZZI D, et al: Combining lisinopril and
L-arginine slows disease progression and reduces endothelin-1 in
passive Heyman nephritis. Kidney Int 64:857–863, 2003
28. REYES AA, PURKERSON ML, KARL I, KLAHR S: Dietary supplemen-
tation with L-arginine ameliorates the progression of renal disease
in rats with subtotal nephrectomy. Am J Kidney Dis 20:168–176,
1992
29. ASHAB I, PEER G, BLUM M, et al: Oral administration of L-arginine
and captopril in rats prevents chronic renal failure by nitric oxide
production. Kidney Int 47:1515–1521, 1995
30. RODRı´GUEZ-ITURBE B, VAZIRI ND, HERRERA-ACOSTA J, JOHNSON RJ:
Oxidative stress, renal infiltration of immune cells and salt-sensitive
hypertension: All for one and one for all. Am J Physiol Renal Physiol
286:F606–F616, 2004
31. RANGAN GK, WANG Y, HARRIS DC: Pharmacologic modulators of
nitric oxide exacerbate tubulointerstitial inflammation in protein-
uric rats. J Am Soc Nephrol 12:1696–1705, 2001
S-86 Rodrı´guez-Iturbe et al: Tubulointerstitial damage and progression of renal failure
32. FUJIHARA CK, MALHEIROS DM, ZATZ R, NORONHA ID: Mycophe-
nolate mofetil attenuates renal injury in the rat remnant kidney.
Kidney Int 54:1510–1519, 1998
33. ROMERO F, RODRIGUEZ-ITURBE B, PARRA G, et al: Mycophenolate
mofetil prevents the progressive renal failure induced by 5/6 renal
ablation in rats. Kidney Int 55:945–955, 1999
34. FUJIHARA CK, DE LOURDES NORONHA I, MALHEIROS, et al: Combined
mycophenolate mofetil and losartan therapy arrests established in-
jury in the remnant kidney. J Am Soc Nephrol 11:283–290, 2000
35. RODRIGUEZ-ITURBE B, QUIROZ Y, SHAHKARAMI A, et al: Mycophe-
nolate mofetil ameliorates nephropathy in the obese Zucker rat.
Kidney Int 68:1041–1047, 2005
36. XU Z-G, LANTING L, VAZIRI ND, et al: Upregulation of angiotensin II
type 1 receptor, inflammatory mediators, and enzymes of arachido-
nate metabolism in obese Zucker rat kidney. Circulation 111:1962–
1969, 2005
37. VANEGAS V, FERREBUZ A, QUIROZ Y, RODRIGUEZ-ITURBE B: Hyper-
tension in Page (cellophane-wrapped) kidney is due to interstitial
nephritis. Kidney Int 68:1161–1170, 2005
38. HAUSER IA, RENDERS L, RADEKE H-H, et al: Mycophenolate mofetil
inhibits rat and human mesangial cell proliferation by guanosine
depletion. Nephrol Dial Transplant 14:58–63, 1999
39. BADID C, VINCENT M, MCGREGOR B, et al: Mycophenolate mofetil
reduces myofibroblast infiltration and collagen III deposition in rat
remnant kidney. Kidney Int 58:51–61, 2000
40. TAO Y, KIM J, SCHRIER RW, EDELSTEIN CL: Rapamycin markedly
slows disease progression in a rat model of polycystic kidney disease.
J Am Soc Nephrol 16:46–51, 2005
41. NEGRI AL: Prevention of progressive fibrosis in chronic renal dis-
eases: Antifibrotic agents. J Nephrol 17:496–503, 2004
42. MCDONALD GA, SARKAR P, RENNKE H, et al: Relaxin increases
ubiquitin-dependent degradation of fibronectin in vitro and amelio-
rates renal fibrosis in vivo. Am J Physiol Renal Physiol 285:F59–F67,
2003
43. GARBER SL, MIROCHNIK Y, BRECKLIN CS, et al: Relaxin decreases
renal interstitial fibrosis and slows progression of renal disease. Kid-
ney Int 59:876–872, 2001
44. SHIMIZU H, MARUYAMA S, YUZAWA Y, et al: Anti-monocyte chemoat-
tractant protein-1 gene therapy attenuates renal injury induced
by protein-overload proteinuria. J Am Soc Nephrol 14:1496–1505,
2003
45. TAKASE O, HIRAHASHI J, TAKAYANAGI A, et al: Gene transfer of trun-
cated IjBa prevents tubulointerstitial injury. Kidney Int 63:501–513,
2003
46. WOLF SC, BREHM BR, GASCHKER P, et al: Protective effects of en-
dothelin antagonists in chronic renal failure. Nephrol Dial Trans-
plant 14(Suppl 4):S29–30, 1999
47. ARIMA S, KOHAGURA K, XU HL, et al: Non-genomic vascular action
of aldosterone in glomerular microcirculation. J Am Soc Nephrol
14:2255–2263, 2003
48. SCHAIER M, JOCKS T, GRO¨NE HJ, et al: Retinoid agonist isotretinoin
ameliorate obstructive renal injury. J Urol 170:1398–1402, 2003
49. KHULMANN A, HAAS CS, GROSS ML, et al: 1,25-dihydroxyvitamin D
decreases podocyte loss and podocyte hypertrophy in the subtotally
nephrectomized rat. Am J Physiol Renal Physiol 286:F526–F533,
2004
50. KANG DH, HUGHES J, MAZZALI M, et al: Impaired angiogenesis in
the remnant kidney model. II. Vascular endothelial growth factor
administration reduces renal fibrosis and stabilizes renal function.
J Am Soc Nephrol 12:1448–1457, 2001
51. KANG DH, PARK EY, YU ES, et al: Renoprotective effect of ery-
thropoietin (EPO): Possibly via an amelioration of renal hypoxia
with stimulation of angiogenesis in the kidney. Kidney Int 67:1683,
2005
52. LIU Y, RAJUR K, TOLBERT E, DWORKIN LD: Endogenous hepatocyte
growth factor ameliorates chronic renal injury by activating matrix
degradation pathways. Kidney Int 58:2028–2043, 2000
53. MIZUNO S, MATSUMOTO K, WEN J, NAKAMURA T: Hepatocyte growth
factor suppresses interstitial fibrosis in a mouse model of obstructive
nephropathy. Kidney Int 59:1304–1314, 2001
54. ZEISBERG M, HANAI J, SUGIMOTO H, et al: BMP-7 counteracts
TGF-b 1-induced epithelial-to-mesenchymal transition and reverses
chronic renal injury. Nat Med 9:964–968, 2003
55. WANG S, CHEN Q, SIMON TC, et al: Bone morphogenic protein-
7 (BMP-7), a novel therapy for diabetic nephropathy. Kidney Int
63:2037–2049, 2003
56. NAGATOYA K, MORIYAMA T, KAWADA N, et al: Y-27632 prevents
tubulointerstitial fibrosis in mouse kidneys with unilateral ureteral
obstruction. Kidney Int 61:1684–1695, 2002
57. ZIYADEH FN, HOFFMAN BB, HAN DC, et al: Long-term prevention of
renal insufficiency, excess matrix expression and glomerular mesan-
gial matrix expansion by treatment with monoclonal antitransform-
ing growth factor-b antibody in db/db diabetic mice. Proc Natl Acad
Sci USA 97:8015–8020, 2000
58. YOKOI H, MUKOYAMA M, NAGAE T, et al: Reduction in connective
tissue growth factor by antisense treatment ameliorates renal tubu-
lointerstitial fibrosis. J Am Soc Nephrol 15:1430–1440, 2004
59. WANG S, WILKES MC, LEOF EB, HIRSCHBERG R: Imatinib mesylate
blocks a non-Smad TGF-b pathway and reduces renal fibrogenesis
in vivo. FASEB J 19:1–11, 2005
